98 related articles for article (PubMed ID: 38703592)
1. Multidisciplinary Standards and Evolving Therapies for Patients With Pancreatic Cancer.
Safyan RA; Kim E; Dekker E; Homs M; Aguirre AJ; Koerkamp BG; Chiorean EG
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438598. PubMed ID: 38781541
[TBL] [Abstract][Full Text] [Related]
2. Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy.
Olaoba OT; Adelusi TI; Yang M; Maidens T; Kimchi ET; Staveley-O'Carroll KF; Li G
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791887
[TBL] [Abstract][Full Text] [Related]
3. Evolutionary and immune microenvironment dynamics during neoadjuvant treatment of oesophagael adenocarcinoma.
Barroux M; Househam J; Lakatos E; Ronel T; Baker AM; Salié H; Mossner M; Smith K; Kimberley C; Nowinski S; Berner A; Gunasri V; Jansen M; Caravagna G; Steiger K; Slotta-Huspenina J; Weichert W; Alberstmeier M; Chain B; Friess H; Bengsch B; Schmid R; Siveke J; Quante M; Graham T
Res Sq; 2023 Apr; ():. PubMed ID: 37090678
[TBL] [Abstract][Full Text] [Related]
4. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study.
Kung HC; Yu J
MedComm (2020); 2023 Apr; 4(2):e216. PubMed ID: 36814688
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma - Heading towards a promising change in treatment paradigm.
Mahmood U; Carrier E; Khan K
Cancer Treat Rev; 2024 Jun; 127():102750. PubMed ID: 38703592
[TBL] [Abstract][Full Text] [Related]
7. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
8. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma.
Gray S; de Liguori Carino N; Radhakrishna G; Lamarca A; Hubner RA; Valle JW; McNamara MG
Eur J Surg Oncol; 2022 Jun; 48(6):1198-1208. PubMed ID: 35264307
[TBL] [Abstract][Full Text] [Related]
9. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
Singh RR; O'Reilly EM
Drugs; 2020 May; 80(7):647-669. PubMed ID: 32306207
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
